Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27139104 | 0.83 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31074478 | 0.82 | ALDH1A1 (0.32) | ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL31074613 | 0.82 | SMN1; SMN2 (0.34) | ALDH1A1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20338885 | 0.82 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29189600 | 0.82 | L3MBTL1 (0.36) | ALDH1A1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31074590 | 0.82 | ALDH1A1 (0.37) | ALDH1A1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30079489 | 0.81 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31074571 | 0.81 | SMN1; SMN2 (0.43) | ALDH1A1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30079506 | 0.80 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4016651 | 0.80 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665734-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-20240360137-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| WO-2024171094-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | NOVARTIS AG (CH) | 2024-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360137-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | CDK2, CDK1, CCNK | ALDH1A1 4208/4885L3MBTL1 3476/4885MEN1 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.